Biocon
- INDIAINDIA · 2 min
Biocon sees US generics tariffs as negotiation tactic, not threat
Biocon founder and executive chairperson Kiran Mazumdar-Shaw said the company views the proposed US tariffs on generic drugs as more of a negotiation tactic than a real threat.
07 Aug, 07:28 am IST - FUNDINGFUNDING · 1 min
Mylan sells entire 5.64% stake in Biocon for ₹3,679 crore
Mylan has exited its investment in Biocon by selling its entire 5.64% stake for ₹3,679 crore through block deals, according to thehindubusinessline.com.
15 Jul, 01:22 am IST